{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Dermatofibrosarcome : Questions médicales les plus fréquentes",
"headline": "Dermatofibrosarcome : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Dermatofibrosarcome : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-05",
"dateModified": "2025-03-02",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Dermatofibrosarcome"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Fibrosarcome",
"url": "https://questionsmedicales.fr/mesh/D005354",
"about": {
"@type": "MedicalCondition",
"name": "Fibrosarcome",
"code": {
"@type": "MedicalCode",
"code": "D005354",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.450.795.350"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Dermatofibrosarcome",
"alternateName": "Dermatofibrosarcoma",
"code": {
"@type": "MedicalCode",
"code": "D018223",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Aseel Sleiwah",
"url": "https://questionsmedicales.fr/author/Aseel%20Sleiwah",
"affiliation": {
"@type": "Organization",
"name": "Department of Plastic and Reconstructive Surgery, Southmead Hospital, Southmead Road, Bristol, BS10 5NB, UK. aseelnajeeb@yahoo.com."
}
},
{
"@type": "Person",
"name": "Yoshinao Oda",
"url": "https://questionsmedicales.fr/author/Yoshinao%20Oda",
"affiliation": {
"@type": "Organization",
"name": "Department of Anatomic Pathology, Pathological Sciences, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. oda.yoshinao.389@m.kyushu-u.ac.jp."
}
},
{
"@type": "Person",
"name": "Katherine E Mallett",
"url": "https://questionsmedicales.fr/author/Katherine%20E%20Mallett",
"affiliation": {
"@type": "Organization",
"name": "Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN, U.S.A."
}
},
{
"@type": "Person",
"name": "Ryan M Claxton",
"url": "https://questionsmedicales.fr/author/Ryan%20M%20Claxton",
"affiliation": {
"@type": "Organization",
"name": "Alix School of Medicine, Mayo Clinic, Rochester, MN, U.S.A."
}
},
{
"@type": "Person",
"name": "Peter C Ferguson",
"url": "https://questionsmedicales.fr/author/Peter%20C%20Ferguson",
"affiliation": {
"@type": "Organization",
"name": "Division of Orthopaedic Surgery, Department of Surgery, University of Toronto, Toronto, ON, Canada."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The genotype list string code syntax for exchanging nomenclature-level genotyping results in clinical and research data management and analysis systems.",
"datePublished": "2023-07-05",
"url": "https://questionsmedicales.fr/article/37403548",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/tan.15145"
}
},
{
"@type": "ScholarlyArticle",
"name": "PMTCT Data Management and Reporting during the Transition Phase of Implementing the Rationalised Registers in Amathole District, Eastern Cape Province, South Africa.",
"datePublished": "2022-11-28",
"url": "https://questionsmedicales.fr/article/36497931",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijerph192315855"
}
},
{
"@type": "ScholarlyArticle",
"name": "EnzymeML: seamless data flow and modeling of enzymatic data.",
"datePublished": "2023-02-09",
"url": "https://questionsmedicales.fr/article/36759590",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41592-022-01763-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "Enabling data sharing and utilization for African population health data using OHDSI tools with an OMOP-common data model.",
"datePublished": "2023-06-09",
"url": "https://questionsmedicales.fr/article/37361151",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fpubh.2023.1116682"
}
},
{
"@type": "ScholarlyArticle",
"name": "Health data hubs: an analysis of existing data governance features for research.",
"datePublished": "2023-07-10",
"url": "https://questionsmedicales.fr/article/37430347",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12961-023-01026-1"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Tumeurs",
"item": "https://questionsmedicales.fr/mesh/D009369"
},
{
"@type": "ListItem",
"position": 3,
"name": "Tumeurs par type histologique",
"item": "https://questionsmedicales.fr/mesh/D009370"
},
{
"@type": "ListItem",
"position": 4,
"name": "Tumeurs du tissu conjonctif et des tissus mous",
"item": "https://questionsmedicales.fr/mesh/D018204"
},
{
"@type": "ListItem",
"position": 5,
"name": "Sarcomes",
"item": "https://questionsmedicales.fr/mesh/D012509"
},
{
"@type": "ListItem",
"position": 6,
"name": "Fibrosarcome",
"item": "https://questionsmedicales.fr/mesh/D005354"
},
{
"@type": "ListItem",
"position": 7,
"name": "Dermatofibrosarcome",
"item": "https://questionsmedicales.fr/mesh/D018223"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Dermatofibrosarcome - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Dermatofibrosarcome",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-08",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Dermatofibrosarcome",
"description": "Comment diagnostique-t-on un dermatofibrosarcome ?\nQuels examens complémentaires sont nécessaires ?\nQuels signes cliniques indiquent un dermatofibrosarcome ?\nLe dermatofibrosarcome peut-il être confondu avec d'autres tumeurs ?\nQuel rôle joue l'histopathologie dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D018223?mesh_terms=Data+Management&page=6#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Dermatofibrosarcome",
"description": "Quels sont les symptômes d'un dermatofibrosarcome ?\nLe dermatofibrosarcome provoque-t-il des douleurs ?\nPeut-on observer des changements de couleur sur la lésion ?\nLes démangeaisons sont-elles fréquentes ?\nLa lésion peut-elle saigner ?",
"url": "https://questionsmedicales.fr/mesh/D018223?mesh_terms=Data+Management&page=6#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Dermatofibrosarcome",
"description": "Peut-on prévenir le dermatofibrosarcome ?\nLes personnes à risque doivent-elles être surveillées ?\nL'exposition au soleil influence-t-elle le risque ?\nDes mesures de protection cutanée sont-elles recommandées ?\nLes vaccinations peuvent-elles aider à prévenir le cancer ?",
"url": "https://questionsmedicales.fr/mesh/D018223?mesh_terms=Data+Management&page=6#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Dermatofibrosarcome",
"description": "Quel est le traitement principal du dermatofibrosarcome ?\nLa radiothérapie est-elle utilisée ?\nDes traitements médicamenteux sont-ils disponibles ?\nQuelle est l'importance de la surveillance post-opératoire ?\nPeut-on traiter le dermatofibrosarcome par chimiothérapie ?",
"url": "https://questionsmedicales.fr/mesh/D018223?mesh_terms=Data+Management&page=6#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Dermatofibrosarcome",
"description": "Quelles sont les complications possibles du dermatofibrosarcome ?\nLe dermatofibrosarcome peut-il se propager ?\nComment gérer une récidive de dermatofibrosarcome ?\nLes cicatrices peuvent-elles poser problème après traitement ?\nY a-t-il des risques psychologiques associés ?",
"url": "https://questionsmedicales.fr/mesh/D018223?mesh_terms=Data+Management&page=6#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Dermatofibrosarcome",
"description": "Quels sont les facteurs de risque du dermatofibrosarcome ?\nLes antécédents familiaux jouent-ils un rôle ?\nL'âge influence-t-il le risque de dermatofibrosarcome ?\nLes infections virales sont-elles un facteur de risque ?\nLe sexe influence-t-il le risque de dermatofibrosarcome ?",
"url": "https://questionsmedicales.fr/mesh/D018223?mesh_terms=Data+Management&page=6#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on un dermatofibrosarcome ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'examen clinique et une biopsie pour analyse histologique."
}
},
{
"@type": "Question",
"name": "Quels examens complémentaires sont nécessaires ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens d'imagerie comme l'IRM peuvent être utilisés pour évaluer l'extension tumorale."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent un dermatofibrosarcome ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une lésion cutanée ferme, indolore, souvent pigmentée, qui évolue lentement."
}
},
{
"@type": "Question",
"name": "Le dermatofibrosarcome peut-il être confondu avec d'autres tumeurs ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut être confondu avec des lipomes ou d'autres tumeurs cutanées bénignes."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'histopathologie dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'histopathologie permet de confirmer la nature maligne de la tumeur et son type histologique."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'un dermatofibrosarcome ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent une masse cutanée indolore, souvent avec des bords bien définis."
}
},
{
"@type": "Question",
"name": "Le dermatofibrosarcome provoque-t-il des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "En général, il est indolore, mais des douleurs peuvent survenir si la tumeur est compressive."
}
},
{
"@type": "Question",
"name": "Peut-on observer des changements de couleur sur la lésion ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la lésion peut présenter des variations de couleur, souvent brunâtre ou violacée."
}
},
{
"@type": "Question",
"name": "Les démangeaisons sont-elles fréquentes ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les démangeaisons ne sont pas courantes, mais peuvent survenir dans certains cas."
}
},
{
"@type": "Question",
"name": "La lésion peut-elle saigner ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "La lésion peut saigner, surtout si elle est traumatisée ou si elle est en surface."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir le dermatofibrosarcome ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention spécifique, mais éviter les traumatismes cutanés peut aider."
}
},
{
"@type": "Question",
"name": "Les personnes à risque doivent-elles être surveillées ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes ayant des antécédents familiaux ou des lésions cutanées doivent être surveillées."
}
},
{
"@type": "Question",
"name": "L'exposition au soleil influence-t-elle le risque ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une exposition excessive au soleil peut augmenter le risque de certains cancers cutanés, mais pas spécifiquement du dermatofibrosarcome."
}
},
{
"@type": "Question",
"name": "Des mesures de protection cutanée sont-elles recommandées ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, utiliser des écrans solaires et porter des vêtements protecteurs est conseillé."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles aider à prévenir le cancer ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines vaccinations peuvent prévenir des infections liées à des cancers, mais pas spécifiquement le dermatofibrosarcome."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal du dermatofibrosarcome ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement principal est la chirurgie pour enlever complètement la tumeur."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle utilisée ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La radiothérapie peut être utilisée en complément après la chirurgie pour réduire le risque de récidive."
}
},
{
"@type": "Question",
"name": "Des traitements médicamenteux sont-ils disponibles ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements ciblés peuvent être envisagés dans les cas avancés ou récidivants."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance de la surveillance post-opératoire ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La surveillance est cruciale pour détecter rapidement toute récidive de la tumeur."
}
},
{
"@type": "Question",
"name": "Peut-on traiter le dermatofibrosarcome par chimiothérapie ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chimiothérapie n'est généralement pas efficace pour le dermatofibrosarcome, sauf cas avancés."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles du dermatofibrosarcome ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la récidive locale et, dans de rares cas, des métastases."
}
},
{
"@type": "Question",
"name": "Le dermatofibrosarcome peut-il se propager ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il a un faible potentiel de métastase, mais peut envahir les tissus voisins."
}
},
{
"@type": "Question",
"name": "Comment gérer une récidive de dermatofibrosarcome ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "La récidive nécessite souvent une nouvelle intervention chirurgicale et un suivi étroit."
}
},
{
"@type": "Question",
"name": "Les cicatrices peuvent-elles poser problème après traitement ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les cicatrices peuvent être inesthétiques et nécessiter des soins ou des interventions esthétiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques psychologiques associés ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le diagnostic et le traitement peuvent entraîner du stress et de l'anxiété chez les patients."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque du dermatofibrosarcome ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents de traumatismes cutanés, des maladies génétiques et l'exposition à des radiations."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de dermatofibrosarcome peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de dermatofibrosarcome ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le dermatofibrosarcome est plus fréquent chez les adultes jeunes, généralement entre 20 et 50 ans."
}
},
{
"@type": "Question",
"name": "Les infections virales sont-elles un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales, comme le virus de l'herpès, peuvent être associées à un risque accru."
}
},
{
"@type": "Question",
"name": "Le sexe influence-t-il le risque de dermatofibrosarcome ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'y a pas de différence significative entre les sexes concernant le risque de dermatofibrosarcome."
}
}
]
}
]
}
The nomenclatures used to describe HLA and killer-cell immunoglobulin-like receptor (KIR) alleles distinguish unique nucleotide and peptide sequences, and patterns of expression, but are insufficient ...
The National Department of Health, in March 2015, launched the implementation of Rationalisation of Register, aimed at reducing the amount of time invested in completing the registers and collecting d...
This study explored the effect of the rollout of Rationalisation of Register on the documentation and reporting of Prevention of Mother-to-Child Transmission (PMTCT) programme data with the existing s...
A mixed-method research approach was used, and three source documents, namely: Tally sheet, Antenatal care (ANC) register, and Tick register used for collecting and reporting PMTCT data, were reviewed...
All selected facilities completed the three source documents. The facilities consolidated their PMTCT data monthly before reporting to the District Health Information System (DHIS). Less than half of ...
PMTCT data management and reporting were challenging during the transitioning phase of implementing the rationalised registers because of different timelines instituted in the facilities and non-avail...
The design of biocatalytic reaction systems is highly complex owing to the dependency of the estimated kinetic parameters on the enzyme, the reaction conditions, and the modeling method. Consequently,...
The COVID-19 pandemic has spurred the use of AI and DS innovations in data collection and aggregation. Extensive data on many aspects of the COVID-19 has been collected and used to optimize public hea...
Digital transformation in healthcare and the growth of health data generation and collection are important challenges for the secondary use of healthcare records in the health research field. Likewise...
To capture the different data governance behind health data hubs across Europe, a survey focused on analysing the feasibility of linking individual-level data between data collections and the generati...
In total, 41 survey responses received until June 2022 were analysed. Stratification methods were performed to cover the different levels of granularity identified in some data hubs' characteristics. ...
The analysis of the responses from health data hub respondents across Europe provided a list of the most frequent aspects, which concluded with a set of specific best practices on data management and ...
Previous research has shown that while missing data are common in bioarchaeological studies, they are seldom handled using statistically rigorous methods. The primary objective of this article is to e...
Missing data were simulated on complete datasets of ordinal (n = 287) and continuous (n = 369) bioarchaeological data. Missing values were imputed using five imputation methods (mean, predictive mean ...
In all instances, listwise deletion was least successful at approximating the original parameters. Imputation of continuous data was more effective than ordinal data. Overall, no one method performed ...
These findings support the use of imputation methods over deletion for handling missing bioarchaeological and paleopathology data, especially when the data are continuous. Whereas deletion methods red...
We investigated the association between various food groups and obesity in Japanese patients with type 2 diabetes....
2070 patients with type 2 diabetes who attended 26 diabetes clinics throughout Japan were analyzed and were divided into obese and non-obese groups. Intakes of food groups determined by a food frequen...
Non-obese patients consumed a larger variety of food groups than obese patients, with the diets of non-obese individuals closer to the traditional Japanese diet characterized by fish, seaweed, and soy...
Food groups and their combinations that were strongly associated with obesity in Japanese patients with type 2 diabetes were identified. Our findings also suggested an inverse association between the ...
The adoption of new technologies in clinical care systems has propitiated the availability of a great amount of valuable data. However, this data is usually heterogeneous, requiring its harmonization ...
The framework includes an ontology-based common data model (i.e. SCDM), a data transformation pipeline and a semantic query system. Heterogeneous datasets, mapped to different terminologies, are integ...
Several datasets from different European institutions have been integrated by using the framework in the context of the European H2020 Precise4Q project. Through the query system, data scientists were...
The flexible data representation using RDF, together with the formal semantic underpinning provided by the SCDM, have enabled the semantic integration, query and advanced exploitation of heterogeneous...
The German initiative "National Research Data Infrastructure for Personal Health Data" (NFDI4Health) focuses on research data management in health research. It aims to foster and develop harmonized in...
Telecommunication (telco) cloud services have emerged as crucial components in the modern digital landscape, offering extensive capabilities for data management, connectivity, and service provision. H...